Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Hemoglobinopathy includes a range of disorders, which occur due to altered structure of hemoglobin. Hemoglobin is present in the red blood cells that transport oxygen from the lungs to the body. Hemoglobinopathy disorder is inherited and are passed on from one generation to another. It is further classified into two categories – thalassemia syndrome and structural hemoglobin variants. Thalassemia syndrome includes disorder related to synthesis defect. The synthesis defect of alpha globin gives rise to alpha thalassemia and defect in beta globin give rise to beta thalassemia. The structural hemoglobin variants occur due to alteration of alpha and beta chains that cause defect in structure.

Hemoglobinopathy Treatment Drugs Market - Impact of Coronavirus (Covid-19) Pandemic

The pandemic of COVID-19 has significantly augmented demand for several drugs. The correct treatment and management of infection by coronavirus (COVID-19) in patients affected by rare hematological diseases may be challenging due to the rapid spread of the pandemic and limited literature so far, especially in some countries such as U.K, U.S. Italy, Face, Spain, Russia, India and others. Patients with certain hemoglobinopathies are more prone to get infected by coronavirus infection. For instance, in June 2020, according to survey carried out by European Hematology Association (EHA) Annual Congress, many patients with hemoglobinopathies, predominantly those with sickle cell disease, were infected with severe acute respiratory syndrome coronavirus.

The hemoglobinopathy treatment drugs market is estimated to be valued at US$ 3.3 billion in 2020 and is expected to exhibit a CAGR of 8.4% during the forecast period (2020-2027).

Figure 1. Hemoglobinopathy Treatment Drugs Market Share (%) Analysis, By Drug Type, 2020

Hemoglobinopathy Treatment Drugs  | Coherent Market Insights

Increasing prevalence of hemoglobinopathies and product approvals are expected to boost growth of the hemoglobinopathy treatment drugs market

The rising prevalence of hemoglobinopathies such as thalassemia is expected to propel the hemoglobinopathy treatment drugs market growth over the forecast period. For instance, according to a report of Pediatric Blood Cancer 2018, alpha thalassemia is the most common single-gene disorder in the world. It is estimated that there are 270 million carriers of mutant globin genes that can potentially cause severe forms of thalassemia. Moreover, 300,000-400,000 severely affected infants are born every year, more than 95% of whom are in Asia, or in the Middle East.

Furthermore, the hemoglobinopathy treatment drugs market is expected to witness significant growth in the near future, owing to increasing product approvals by regulatory bodies. For instance, in November 2019, Celgene Corporation and Acceleron Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) approved REBLOZYL (luspatercept-aamt) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Hemoglobinopathy Treatment Drugs Market - Restraints

Failing clinical trials for the treatment of sickle cell anemia is expected to hinder the hemoglobinopathy treatment drugs market growth. For instance, in August 2019, Pfizer Inc. announced that the Phase III Rivipansel pivotal study, to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease, failed to achieve its primary or key secondary efficacy endpoints for pediatric patients.

Moreover, lack of a permanent cure for hemoglobinopathy disorders is also expected to limit the market growth. Most treatment options that are available focus on reducing symptoms of the disorders and the only reliable treatment available is bone marrow transplant, which is a very complex and expensive procedure and is also associated with some side effects.

request-sample

Hemoglobinopathy Treatment Drugs Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 3.3 Bn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 8.4% 2027 Value Projection: US$ 6.4 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Analgesics, Antibiotics, ACE Inhibitors, Hydroxyurea, Others.
  • By Disease Type: Thalassemia, Sickle Cell Disease, Other Hb Variants Diseases.
  • By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Bristol-Myers Squibb Company, GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company Ltd., Novartis International AG, Bluebird Bio Inc., HemaQuest Pharmaceuticals Inc., Emmaus Medical Inc., Prolong Pharmaceuticals, Merck & Co., Inc., Medunik USA Inc., Sangamo Therapeutics, Inc., Global Blood Therapeutics, Alnylam Pharmaceuticals, and Acceleron Pharma, Inc.

Growth Drivers:
  • Increasing prevalence of blood disorders
  • The increasing number of product approvals and launches
Restraints & Challenges:
  • Failure of drugs
  • Lack of permanent cure

Hemoglobinopathy Treatment Drugs Market – Regional Analysis

North America is estimated to account for the largest share in the hemoglobinopathy treatment drugs market in 2020, owing to increasing product approvals by regulatory bodies in North America region. For instance, in May 2020, CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX001, an investigational, autologous, gene-edited hematopoietic stem cell therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

Furthermore, the increasing prevalence of hemoglobinopathies in Asia Pacific, Middle East, and Africa region is expected to drive the hemoglobinopathy treatment drugs market growth in the near future. For instance, in 2018, according to a report of Pediatric Blood Cancer 2018, the frequency of alpha thalassemia alleles in genes is 5-10% in the Mediterranean basin, 20-30% in portions of West Africa, and as high as 60-80% in parts of Saudi Arabia, India, Thailand, Papua New Guinea, and Melanesia. In Thailand, which has a population of 62 million people, around 7,000 infants are born each year with hemoglobin H disease.

Figure 2. Hemoglobinopathy Treatment Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Hemoglobinopathy Treatment Drugs  | Coherent Market Insights

Hemoglobinopathy Treatment Drugs Market - Competitive Landscape

Key players operating in the hemoglobinopathy treatment drugs market include Bristol-Myers Squibb Company, GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company Ltd., Novartis International AG, Bluebird Bio Inc., HemaQuest Pharmaceuticals Inc., Emmaus Medical Inc., Prolong Pharmaceuticals, Merck & Co., Inc., Medunik USA Inc., Sangamo Therapeutics, Inc., Global Blood Therapeutics, Alnylam Pharmaceuticals, and Acceleron Pharma, Inc.

Hemoglobinopathy is a group of hereditary blood disorders involving an abnormality in the structure of hemoglobin. These disorders include both sickle cell disease (SCD) and thalassemia. Common symptoms of the condition include severe pain, shortness of breath, enlarged spleen, and growth problems in children. Other types of hemoglobinopathies linked to the structural hemoglobin variants are HbS, HbE, and HbC. The highly variable clinical manifestations of the hemoglobinopathies range from mild hypochromic anemia to moderate hematological disease to severe, lifelong, transfusion-dependent anemia with multiorgan involvement. Drugs to treat the symptoms of hemoglobinopathy include analgesics, antibiotics, ACE inhibitors, and hydroxyurea. According to the data of National Center for Biotechnology Information, more than 90% of patients currently survive the adulthood. Optimally treated patients have a projected life span of 50 to 60 years.

Market Dynamics

Increasing incidence and prevalence of sickle cell disease (SCD) is expected to propel growth of the global hemoglobinopathy treatment drugs market over the forecast period. For instance, according to the data published in Centers for Disease Control and Prevention in October 2019, SCD affects around 100,000 Americans every year. Moreover, as per the same source, around 1 in 13 African-American babies are born with sickle cell trait (SCT).

However, failing clinical trials for the treatment of sickle cell anemia are expected to hinder the market growth. For instance, in August 2019, Pfizer Inc. announced that the Phase III Rivipansel pivotal study, to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease, failed to achieve its primary or key secondary efficacy endpoints. Moreover, high costs, and difficulties associated with diagnosis of hemoglobinopathies such as lack of proper knowledge and lack of skilled professionals are expected to restrain growth of the market up to certain extent.

Key features of the study:

  • This report provides in-depth analysis of the global hemoglobinopathy treatment drugs market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global hemoglobinopathy treatment drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Bristol-Myers Squibb Company, GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company Ltd., Novartis International AG, Bluebird Bio Inc., HemaQuest Pharmaceuticals Inc., Emmaus Medical Inc., Prolong Pharmaceuticals, Merck & Co., Inc., Medunik USA Inc., Sangamo Therapeutics, Inc., Global Blood Therapeutics, Inc., Alnylam Pharmaceuticals, and Acceleron Pharma, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global hemoglobinopathy treatment drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hemoglobinopathy treatment drugs market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Hemoglobinopathy Treatment Drugs Market, By Drug Type:
    • Analgesics
    • Antibiotics
    • ACE Inhibitors
    • Hydroxyurea
    • Others
  • Global Hemoglobinopathy Treatment Drugs Market, By Disease Type:
    • Thalassemia
    • Sickle Cell Disease
    • Other Hb Variants Diseases
  • Global Hemoglobinopathy Treatment Drugs Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Hemoglobinopathy Treatment Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Type:
        • Analgesics
        • Antibiotics
        • ACE Inhibitors
        • Hydroxyurea
        • Others
      • By Disease Type:
        • Thalassemia
        • Sickle Cell Disease
        • Other Hb Variants Diseases
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Type:
        • Analgesics
        • Antibiotics
        • ACE Inhibitors
        • Hydroxyurea
        • Others
      • By Disease Type:
        • Thalassemia
        • Sickle Cell Disease
        • Other Hb Variants Diseases
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Type:
        • Analgesics
        • Antibiotics
        • ACE Inhibitors
        • Hydroxyurea
        • Others
      • By Disease Type:
        • Thalassemia
        • Sickle Cell Disease
        • Other Hb Variants Diseases
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Type:
        • Analgesics
        • Antibiotics
        • ACE Inhibitors
        • Hydroxyurea
        • Others
      • By Disease Type:
        • Thalassemia
        • Sickle Cell Disease
        • Other Hb Variants Diseases
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC Countries
        • Israel
        • Rest of Middle East
      • By Drug Type:
        • Analgesics
        • Antibiotics
        • ACE Inhibitors
        • Hydroxyurea
        • Others
      • By Disease Type:
        • Thalassemia
        • Sickle Cell Disease
        • Other Hb Variants Diseases
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Type:
        • Analgesics
        • Antibiotics
        • ACE Inhibitors
        • Hydroxyurea
        • Others
      • By Disease Type:
        • Thalassemia
        • Sickle Cell Disease
        • Other Hb Variants Diseases
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
  • Online Pharmacies
    • Company Profiles
      • Bristol-Myers Squibb Company*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • GlycoMimetics Inc.
    • Pfizer Inc.
    • Anthera Pharmaceuticals Inc.
    • Eli Lilly and Company
    • Mast Therapeutics
    • Daiichi Sankyo Company Ltd.
    • Novartis International AG
    • Bluebird Bio Inc.
    • HemaQuest Pharmaceuticals Inc.
    • Emmaus Medical Inc.
    • Baxter International Inc.
    • Prolong Pharmaceuticals
    • Medunik USA Inc.
    • Sangamo Therapeutics, Inc.
    • Global Blood Therapeutics, Inc.
    • Alnylam Pharmaceuticals
    • Acceleron Pharma, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Disease Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • COVID-19 Impact on Market
      • Pre-COVID 19 Situation
      • Post-COVID 19 Situation
    • Market Trends
    • Epidemiology
    • Regulatory Scenario
    • Reimbursement Scenario
    • New Product Launches/Approvals
    • Mergers & Acquisitions
    • Porter’s Analysis
    • PEST Analysis
  4. Global Hemoglobinopathy Treatment Drugs Market COVID-19 Impact Analysis
      • Pre-COVID 19 Situation
      • Post-COVID 19 Situation
      • Strategies
  5. Global Hemoglobinopathy Treatment Drugs Market, By Drug Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Analgesics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Antibiotics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • ACE Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Hydroxyurea
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Hemoglobinopathy Treatment Drugs Market, By Disease Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Thalassemia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Sickle Cell Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Other Hb Variants Diseases
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Hemoglobinopathy Treatment Drugs Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  8. Global Hemoglobinopathy Treatment Drugs Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  9. Competitive Landscape
    • Company Profiles
      • Bristol-Myers Squibb Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • GlycoMimetics Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Anthera Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Mast Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Daiichi Sankyo Company Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bluebird Bio Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • HemaQuest Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Emmaus Medical Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Baxter International Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Prolong Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Medunik USA Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sangamo Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Global Blood Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Alnylam Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Acceleron Pharma, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 31 market data tables and 27 figures on "Global Hemoglobinopathy Treatment Drugs Market” - Forecast to 2027”

Frequently Asked Questions

The CAGR of the hemoglobinopathy treatment drugs market will be 8.4% during the forecast period (2020-2027).
The value of hemoglobinopathy treatment drugs market is estimated to be US$ 3.3 billion in 2020.
The prominent players in the global hemoglobinopathy treatment drugs market include Bristol-Myers Squibb Company, GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company Ltd., Novartis International AG, Bluebird Bio Inc., Sangamo Therapeutics, Inc., Global Blood Therapeutics, and Acceleron Pharma, Inc.
The hemoglobinopathy treatment drugs market is expected to be valued at US$ 6.4 billion in 2027.
North America is the major region in the hemoglobinopathy treatment drugs market.
The increasing prevalence of blood disorders, and the increasing number of product approvals and launches are expected to drive growth of the hemoglobinopathy treatment drugs market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner